Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTBZ-APEG-PCL nanoparticles
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TTBZ-APEG-PCL nanoparticles are an experimental, brain-targeted nanomedicine designed for the treatment of Huntington's disease. The formulation consists of the small molecule drug tetrabenazine (TTBZ) encapsulated within a biodegradable polymeric matrix composed of poly(epsilon-caprolactone) (PCL) and poly(ethylene glycol) (PEG). The surface of the nanoparticle is functionalized with Angiopep-2 (APEG), a peptide ligand that specifically binds to the low-density lipoprotein receptor-related protein 1 (LRP1) expressed on the blood-brain barrier. This targeting mechanism facilitates the transport of the nanoparticles into the central nervous system via receptor-mediated transcytosis. Once in the brain, the sustained release of tetrabenazine inhibits the vesicular monoamine transporter 2 (VMAT2), thereby reducing the chorea symptoms associated with Huntington's disease while potentially minimizing peripheral side effects and improving the drug's pharmacokinetic profile.
- Other names
- Tetrabenazine-loaded Angiopep-2-PEG-PCL nanoparticlesANG-PEG-PCL-TTBZ
02
Targets
LRP1 (Prolow-density lipoprotein receptor-related protein 1)PIAS1 (Protein inhibitor of activated STAT 1)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on TTBZ-APEG-PCL nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTBZ-APEG-PCL nanoparticles.